Brief: Cytodyn Submits Breakthrough Therapy Designation Application To FDA For Leronlimab As A Treatment For Metastatic Triple-Negative Breast Cancer
08/11/2021 11:09
Nov 8 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN SUBMITS BREAKTHROUGH THERAPY DESIGNATION
APPLICATION TO
FDA FOR LERONLIMAB AS A TREATMENT FOR METASTATIC TRIPLE-NEGATIVE
BREAST CANCER (MTNBC); FAST TRACK DESIGNATION FOR MTNBC WAS
RECEIVED PREVIOUSLY
Source text for Eikon: ID:nGNX24GCCY
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer